References
- Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379–89.
- Hauser RA, McDermott MP, Messing S, for the Parkinson Study Group. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756–60.
- Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11:327–29.
- Cristina S, Zangaglia R, Mancini F, et al. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003;26:146–50.
- Chase TN, Bibbiani F. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003;5:139–46.
- Samadi P, Gregoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040–51.
- Mela F, Marti M, Dekundy A, et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007;101:483–97.
- Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243–50.
- Stocchi F, Destee A, Hattori N, et al. A 13-week, double-blind, placebo-controlled study of AFQ056, a metabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa-induced dyskinesias. Abstract at the 15th International Congress of Parkinson's Disease and Movement Disorders, Toronto, Canada, June 5–9, 2011.
- Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75–81.
- Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179–86.
- Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011;26:813–18.